News
A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...
Hosted on MSN9mon
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trialhigh-cost treatments that target a patient's genetic source or cell to cure or significantly alter the course of a disease. Pfizer on Wednesday said its experimental gene therapy for a rare ...
The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyretin ...
2d
24/7 Wall St. on MSNPrediction: 1 Biotech Stock That Could Surpass Pfizer by 2030Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
A total of three cases of Creutzfeldt-Jakob disease, a rare and incurable brain condition, have been detected in Hood River ...
Paid and presented by Pfizer. To everyone except his family ... are helping the healthcare community recognise and diagnose rare diseases and support patients more confidently.
Hosted on MSN11mon
Pfizer Pauses Gene Therapy Trial for Muscle Disease After DeathThat study is looking at the gene therapy, called fordadistrogene movaparvovec, to treat Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease that primarily affects boys.
and rare diseases. It also develops and manufactures vaccines. Pfizer collaborated with German biotech company BioNTech SE (BNTX) to develop one of the world's most widely used mRNA-based vaccines ...
The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...
Shares of Pfizer Inc (NYSE:PFE) dipped 1.5% as the pharmaceutical giant announced the discontinuation of its drug candidate danuglipron, which was under investigation for chronic weight management.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
On December 1, Pfizer became the first big pharma to commit to take to market a late-stage biologic drug produced in plant cells. It acquired rights to taligurase alfa, a form of the enzyme ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results